Market closedNon-fractional

PTC Therapeutics/PTCT

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About PTC Therapeutics

PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.

Ticker

PTCT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

South Plainfield, United States

Employees

1,022

PTC Therapeutics Metrics

BasicAdvanced
$2.3B
Market cap
-
P/E ratio
-$7.68
EPS
0.67
Beta
-
Dividend rate
$2.3B
0.67
2.034
1.896
-225.609
-252.862
-1.82%
-10.29%
85.72%
2.47
-2.6
-1.78
-11.51
20.39%
-2.77%
29.16%
4.74%

What the Analysts think about PTC Therapeutics

Analyst Ratings

Majority rating from 13 analysts.
Hold

PTC Therapeutics Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-43.55% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$210M
-31.56%
Net income
-$92M
-41.23%
Profit margin
-43.55%
-14.12%

PTC Therapeutics Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.29%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$2.66
-$1.76
-$2.06
-$1.20
-
Expected
-$1.24
-$1.17
$0.50
-$1.24
-$1.07
Surprise
113.71%
50.36%
-515.71%
-3.29%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for PTC Therapeutics stock?

PTC Therapeutics (PTCT) has a market cap of $2.3B as of July 04, 2024.

What is the P/E ratio for PTC Therapeutics stock?

The price to earnings (P/E) ratio for PTC Therapeutics (PTCT) stock is 0 as of July 04, 2024.

Does PTC Therapeutics stock pay dividends?

No, PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next PTC Therapeutics dividend payment date?

PTC Therapeutics (PTCT) stock does not pay dividends to its shareholders.

What is the beta indicator for PTC Therapeutics?

PTC Therapeutics (PTCT) has a beta rating of 0.67. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell PTC Therapeutics stock

Buy or sell PTC Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing